Almac provides world-class integrated research, development and manufacturing services to over 600 companies, including all the market leaders within the pharmaceutical and biotechnology sectors.
Created by an investment of $600 million by our chairman, Sir Allen McClay, CBE, Almac employs approximately 2,000 exceptional people within the US and EU. Our aim is to utilise the expertise within the Almac organisation to provide a seamless, fast and efficient route from drug discovery through to market.
Almac is comprised of five divisions, namely Almac Diagnostics, Almac Sciences, Almac Clinical Services, Almac Clinical Technologies and Almac Pharma Services. Whilst the strength of Almac is founded on the integration of our combined services, our customers also have the choice to select individual services specific to their own requirements.
Almac's ambition is to be the leader in a generation of superior solutions for the advancement of human health.
A leader in the provision of genomic based solutions for the advancement of patient care, Almac Diagnostics is split into two areas of business - the genomic services division and the diagnostics division.
The genomic services business provides an all-inclusive, ISO17025 accredited, microarray-based expression profiling service, along with expert bioinformatics support, to academia, and biotech and pharmaceutical companies. These services include analysis on our unique Disease Specific Arrays (DSA™) - the first high-density, proprietary, transcriptome-based arrays - a tool that works with paraffin embedded tissue to enables you to learn more about the disease entity
The Diagnostics Division, using the proprietary DSA™, develops new tests for improving the diagnosis and treatment of cancer, which will change the way cancers are managed in the future.
The Almac Sciences division provides custom synthesis services and products to the global pharmaceutical and biotechnology industries, supporting drug discovery to commercialisation.
Almac is involved in many activities including milligram to multi tonne synthesis, building blocks, scaffold and libraries, synthesis of potent and cytotoxic compounds, peptide synthesis - cGMP and non cGMP for all services and scales, analytical and bio-analytical services (GMP and GLP compliant), and synthesis and formulation of labelled compounds (pre-clinical and clinical).
Almac Clinical Services provides a global service for the manufacturing, packaging, labelling, distribution, returns and analysis of clinical trial supplies.
These services include comparator sourcing, manufacture and blinding, label printing, distribution via a global network of local and regional depots, web-based patient randomisation (WebEZ™), integrated IVRS and clinical supplies management service (with Almac Clinical Technologies), and drug supply management, amongst others.
ALMAC CLINICAL TECHNOLOGIES
Almac Clinical Technologies specialises in integrated technology and service-based solutions to accelerate the clinical trial process, reduce costs and improve data quality.
Almac Clinical Technologies provides Interactive Voice and Web Response Systems (IXRS™ ) for patient tracking. Patient randomisation includes centralised randomisation, stratified randomisation and adaptive / balancing algorithms.
Almac can also provide:
ALMAC PHARMA SERVICES
Almac Pharma Services provides formulation development through commercial scale manufacture, packaging, QP release and distribution of the finished product.
In the area of formulation development / analytical support, Almac Pharma Services can offer:
Almac can also produce tablets, capsules and powders in commercial manufacturing. Packaging can be provided in the form of thermoform or coldform blisters, sachets or pouches, wallet cards or containers. Almac can also offer secondary labelling and packaging of unlabelled stock (brite).